Takeda Pharmaceutical Company Limited Deferred Tax Relating To Items Charged Or Credited Directly To Equity
Takeda Pharmaceutical Company Limited (TKPHF) reported Deferred Tax Relating To Items Charged Or Credited Directly To Equity of JPY 506.00 million for the 12-month period ending 2024-03-31, per its 20-F filed 2024-06-26.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2024-06-26
| Period end | Deferred Tax Relating To Items Charged Or Credited Directly To Equity 12 month |
|---|---|
| 2024-03-31 | 506.00M JPY 20-F · filed 2024-06-26 |
| 2023-03-31 | 2.20B JPY 20-F · filed 2024-06-26 |
| 2022-03-31 | -1.46B JPY 20-F · filed 2023-06-28 |
| 2021-03-31 | -730.00M JPY 20-F · filed 2022-06-29 |
| 2020-03-31 | 0.00 JPY 20-F · filed 2021-06-29 |
| 2019-03-31 | -1.99B JPY 20-F · filed 2020-06-24 |